The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry
Shaping the future: after 18 months of research and consultation with members and industry leaders, we’re proud to share our 10-year Vision for the UK life sciences sector. Vision 2035 outlines a bold roadmap for building a stronger, more resilient biotech ecosystem - one with a robust long-term capital base that supports both early and later-stage companies. To turn this vision into reality, we must focus on the areas with the greatest potential for impact.
Call for nominations! Join the BIA Board
We are delighted to invite nominations from individuals interested in joining the BIA Board. This year, five positions are available - four for 'Corporate' members and one for 'Other' members. The application deadline is Friday, 12 September 2025.
UK biotech attracts £1.23 billion in H1 2025
The latest data shows UK biotech is on track to exceed 2024’s total investment, with £1.23 billion raised in the first half of the year. Discover how the sector continues to thrive despite global market headwinds - featuring standout funding rounds, major acquisitions, and progress on unlocking institutional capital.

Influencing and shaping our sector: April - June 2025
This quarter has seen a cascade of government policy announcements, including the Spending Review and Industrial Strategy. We have been rigorously scrutinising and gearing up for the launch of the Life Sciences Sector Plan and the NHS 10-Year Health Plan, two transformative frameworks that could redefine the future of our sector.
Functional genomics explainer: a unique opportunity for the UK
Functional genomics is a vital field in delivering the promise of precision medicine. By moving beyond genome sequencing to understand how genetic variation shapes biological function, this area is unlocking new possibilities for targeted treatments and improved patient outcomes.

Vision 2035: Shaping the future of UK life sciences
After 18 months of in-depth research and consultation with members and industry leaders, we’re proud to share our 10-Year Vision for the UK life sciences sector. Vision 2035 outlines a bold roadmap for building a stronger, more resilient biotech ecosystem—one with a robust long-term capital base that supports both early and later-stage companies. To turn this vision into reality, we must collectively focus on the areas with the greatest potential for impact.
Oligos explainer: A new frontier in precision medicine
Read our latest report outlining how oligonucleotide therapies, an emerging class of complex medicines, are revolutionising how we treat diseases, from rare genetic disorders to broader applications in protein regulation.
First-of-its-kind Women in biotech leadership report just launched!
Offering a deep dive into gender representation at the CEO and C-suite level in UK biotech, this report sheds light on the barriers that still exist for women in leadership and those aspiring to reach these roles. While we’re pleased to see progress in representation, challenges remain - particularly in securing investment, overcoming bias, and achieving inclusive leadership at the highest levels.

Latest UK biotech financing insights just published!
The UK biotech sector achieved significant growth in 2024, raising £3.5 billion in investment — a staggering 94% increase compared to the previous year. This represents the highest annual figure since the £4.5 billion raised in 2021 and is a testament to the sector’s resilience, innovation, and global appeal, even in the face of challenging economic conditions.
PULSE 2025: Are you ready to turn your big ideas into reality?
This free, three-day bootcamp for biotech entrepreneurs offers practical skills, advice and connections to give you the knowledge and inspiration to become a successful start-up founder. Learn from industry leaders, take part in interactive sessions and network with top CEOs and investors who can inspire and support your biotech company.
Just published! 🆕 TechBio: UK leads innovation frontier
Take a look at the recent funding trends, successful partnerships and the challenges faced by SMEs in the TechBio sector. Get inspired by success stories like Baseimmune and BenevolentAI, highlighting how the UK is harnessing technology to improve healthcare and drive meaningful change.
mRNA Revolution: A new generation of medicine
The UK is at the forefront of rapid advancements in mRNA technology which has already demonstrated its enormous potential in the pandemic. This new report shows the breadth and depth of UK mRNA capability not just across academia and industry but also across the UK. It provides updates on the latest advances in mRNA technology and features case studies on how it is currently being used, providing a tangible sense of both the benefits of the technology.
PULSE: Empowering the future of UK biotech
We're thrilled to unveil the launch of our latest report highlighting the role PULSE in advancing biotech innovation across the UK. Since 2018, PULSE has been equipping life science entrepreneurs with essential knowledge and valuable networks, transforming breakthrough research into successful, high-impact ventures 🚀 Discover the impact of PULSE
Biotech and life sciences news and insights

member companies representing UK ecosystem

influence meetings with policymakers

attendees across 45 events hosted

£ saved by BIA members in the past 12 months
Explore opportunities to influence, connect and save with the BIA
Join us at the next BIA event
Secure Innovation: How to protect your company’s IP and competitive advantage

The BIA is a truly exceptional organisation, bringing together companies across the life sciences ecosystem, from Biotech and TechBio to biopharma, big and small. For companies like Relation, being part of this community is invaluable. The BIA not only fosters connection through networking and community events, but also plays a critical role in shaping policy, supporting leadership development, and championing innovation across the UK. We’re proud to be members of such a vibrant and mission-driven network, thank you for all that you do!
Rosie Rodriguez PhD
SVP Growth, Relation Therapeutics

The Wellcome Sanger Institute is proud to be an active member of the BIA. The BIA’s commitment to driving innovation aligns with the Sanger Institute mission. Through the BIA network of like-minded organisations we can expand the reach and impact of Sanger’s science at scale.
Dr Julia Wilson
Director of Strategy, Partnerships and Innovation, Wellcome Sanger Institute

Joining the BIA was an easy decision for Stablepharma, not only to participate in their excellent networking events but also to be part of an organisation that has the focus and lobbying power with relevant government bodies in the UK. It is always good to meet other technology and biotechnology companies within the life sciences space, as well as suppliers and specialists in our industry sector. BIA’s clear commitment to progressing and celebrating the successes of the UK life sciences sector for ultimately, better patient and population healthcare, is truly impressive.
Ozgur Tuncer
CEO and Executive Director, Stablepharma

The BIA is simply the best trade organisation I've been a member of in 40 years of business, well done BIA!
Nick Child
Co-Founder & VP, Stablepharma

Thanks for sending through this [mRNA report] - really interesting and useful piece of work. These sorts of maps and analysis of what we have (and what we don’t have) will be very helpful. As you know, they certainly were during Covid.
Patrick Vallance
UK Minister for Science, Research and Innovation

We’re honoured to be named the BioIndustry Association’s Charity Partner for 2025. This partnership will help us address the disparities in blood cancer outcomes across the UK. We have been working closely with the industry for the last decade, and now with the BIA's support, we will amplify our work to improve survival rates and strive to ensure that no one’s chances of survival are determined by where they live.
Together, we can drive vital change and ensure the UK is a global leader when it comes to blood cancer survival.
Helen Rowntree
CEO of Blood Cancer UK